31
Life Technologies
™
| lifetechnologies.com/parkinsons
References
1. Olanow CW, Stern MB, Sethi K (2009) The scientific and clinical basis for the treatment of
Parkinson disease. Neurology 72(21 Suppl 4):S1–S136.
2. Hockemeyer D, Wang H, Kiani S et al. (2011) Genetic engineering of human pluripotent cells
using TALE nucleases. Nat Biotech 29(8):731–734.
3. Burn DJ, Jaros E (2001) Multiple system atrophy: cellular and molecular pathology. Mol Pathol
54(6):419–426.
4. Zhao J, Hermanson SB, Carlson CB et al. (2012) Pharmacological inhibition of LRRK2 cellular
phosphorylation sites provides insight into LRRK2 biology. Biochem Soc Trans 40(5):1158–1162.
5. Murphy KE, Gysbers AM, Abbott SK et al. (2014) Reduced glucocerebrosidase is associated with
increased α-synuclein in sporadic Parkinson's disease. Brain 137(Pt 3):834–848.
6. Thorvaldsdottir H, Robinson JT, Mesirov, JP (2012) Integrative Genomics Viewer (IGV): high-
performance genomics data visualization and exploration. Brief Bioinform 14(2):178–192.
7. Ding Q, Regan SN, Xia Y et al. (2013) Enhanced efficiency of human pluripotent stem cell genome
editing through replacing TALENs with CRISPRs. Cell Stem Cell 12(4):393–394.
